Anzeige
Mehr »
Mittwoch, 13.08.2025 - Börsentäglich über 12.000 News
Diese Aktie liegt in der Turbo-Zone - und könnte der Gold-Gewinner 2025/26 werden!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQ1X | ISIN: CA0717341071 | Ticker-Symbol: BVF
Tradegate
12.08.25 | 21:44
5,972 Euro
+3,82 % +0,220
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BAUSCH HEALTH COMPANIES INC Chart 1 Jahr
5-Tage-Chart
BAUSCH HEALTH COMPANIES INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,9106,09012.08.
5,9746,02712.08.

Aktuelle News zur BAUSCH HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBausch Health (BHC) Rebounds 15.8% on Bargain-Hunting4
DoBausch Health Companies Inc.: Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners197For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC)...
► Artikel lesen
31.07.Bausch Health Companies Inc. - S-8, Securities to be offered to employees in employee benefit plans4
BAUSCH HEALTH Aktie jetzt für 0€ handeln
31.07.Bausch Health Stock Falls on Q2 Earnings Miss, Revenues Beat22
31.07.Bausch Health reaffirms 2025 revenue target of $4.95B-$5.1B as debt reduction and pipeline expansion advance9
30.07.Bausch Health Companies Inc.: Bausch Health Announces Second Quarter 2025 Results383Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year periodGAAP Net Income Attributable to Bausch Health Companies...
► Artikel lesen
29.07.Bausch Health Companies' Earnings Outlook3
29.07.Bausch Health Companies Inc: Bausch Health to acquire Durect2
29.07.Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout3
29.07.DURECT Corp Stock Surges Nearly 254% On Acquisition Deal With Bausch Health2
29.07.Bausch Health bags phase 3-ready liver prospect in $63M Durect buyout3
29.07.Bausch Health stock rises, Durect flies after acquisition deal3
29.07.Bausch Health to acquire liver drug developer Durect for $1.75 per share10
29.07.Bausch Health To Acquire DURECT; Expanding Liver Disease Pipeline With Larsucosterol432OTTAWA (dpa-AFX) - Bausch Health Companies Inc. (BHC), a pharmaceutical company, on Tuesday announced that it has signed a definitive agreement to acquire DURECT Corp. (DRRX), gaining access...
► Artikel lesen
29.07.Bausch Health übernimmt DURECT für bis zu 413 Mio. US-Dollar und sichert sich Wirkstoff gegen alkoholische Hepatitis20
29.07.Bausch Health to acquire DURECT for $63 million upfront8
29.07.Bausch Health Companies Inc.: Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease320DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the first FDA-approved therapeutic option for the treatment of patients with alcoholic...
► Artikel lesen
29.07.Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease85DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment...
► Artikel lesen
29.07.Bausch Health Companies Inc: Bausch Health unit to redeem $602M of notes Aug. 282
28.07.Bausch Health to redeem ~$602M of outstanding notes due 20269
Weiter >>
138 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,8